Related Experiment Videos

Thromboembolism in patients with decreased left ventricular function: incidence, risk, and treatment

R L Wilensky1, S C Jung

  • 1Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, 46202, USA.

Insights

Intracavitary thrombus occurs in 11-44% of idiopathic dilated cardiomyopathy patients, with embolism risk up to 20%. Acute anterior myocardial infarction also risks thrombus formation (21-41%) and embolism (2-6%), especially with mobile thrombi.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Intracavitary thrombus is a known complication in idiopathic dilated cardiomyopathy (11-44%) and after acute anterior myocardial infarction (21-41%).
  • Embolism risk associated with intracavitary thrombus ranges from 11-20% in dilated cardiomyopathy and 2-6% in acute anterior myocardial infarction.

Purpose of the Study:

  • To review the incidence of intracavitary thrombus and embolism in specific cardiac conditions.
  • To highlight the risk factors for embolization, such as protruding or mobile thrombi.
  • To provide guidance on anticoagulation therapy for patients with dilated cardiomyopathy.

Main Methods:

  • Literature review and synthesis of existing data on intracavitary thrombus and embolism.
  • Analysis of incidence rates and risk factors in patients with idiopathic dilated cardiomyopathy and acute anterior myocardial infarction.
  • Review of current recommendations for systemic anticoagulation.

Main Results:

  • Incidence of intracavitary thrombus in idiopathic dilated cardiomyopathy is 11-44%, with embolism occurring in 11-20%.
  • Acute anterior myocardial infarction shows intracavitary thrombus formation in 21-41% and embolism risk of 2-6%.
  • Protruding or mobile thrombi significantly increase the risk of embolization.

Conclusions:

  • Intracavitary thrombus is a significant concern in both idiopathic dilated cardiomyopathy and post-acute anterior myocardial infarction.
  • Anticoagulation therapy, targeting an international normalized ratio of 2.0-3.0, is recommended for patients with dilated cardiomyopathy.
  • Risk stratification for embolism should consider thrombus characteristics like mobility.

Related Concept Videos